The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Hepatocellular Carcinoma Case Studies

Case Studies: Later Line Therapeutic Decisions in Metastatic HCC

In this case-based interview series, Anthony El-Khoueiry, MD, outlines the most important factors to consider in advanced hepatocellular carcinoma and discusses treatment options in patients who have progressed following therapy with sorafenib.

Later Line Therapeutic Decisions in Metastatic HCC: Case 2

January 2017

  • A 74-year old female with a history of HCV-infection
  • Prior treatment with interferon, achieving sustained virologic response
  • Had recurrence of HCV
  • CT scan showed a 6.5-cm single liver mass with arterial enhancement, venous phase washout, and main portal vein invasion
  • ECOG=1
  • Child-Pugh A
  • Therapy was initiated with sorafenib at 400 BID
  • Patient experienced grade 3 hand-foot skin reaction; dose reduction to 400 QD
  • Patient experienced grade 3 diarrhea; dose reduction to 400 QOD

April 2017

  • Follow-up scans show radiographic progression with lung metastases
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.